Product image of Lercanidipin Accord (Lercanidipine) supplied by GNH India

Lercanidipin Accord

Active Ingredient:
Lercanidipine
Origin:
EU

Lercanidipin Accord (Lercanidipine)

Lercanidipine, the active ingredient in Lercanidipin Accord, is a calcium channel blocker presented as an oral tablet for oral administration. It is used to lower elevated blood pressure in adult patients with hypertension, helping to reduce cardiovascular risk.

GNH India supplies Lercanidipin Accord as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality standards. The product complies with EU regulatory requirements and is available for export to multiple regions. GNH India's global network ensures reliable delivery and support for healthcare providers seeking consistent supply.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lercanidipine is a calcium channel blocker indicated for the management of hypertension.

  • Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
  • Isolated systolic hypertension: helps control elevated systolic pressure, especially in older adults.
  • Hypertensive patients with cardiovascular risk: contributes to overall risk reduction when used with other antihypertensive agents.

How It Works

  • Lercanidipine selectively blocks L-type calcium channels in vascular smooth muscle, preventing calcium influx that is necessary for contraction. This inhibition leads to arterial vasodilation, reduced peripheral resistance, and consequently a decrease in systemic blood pressure without significant effect on heart rate.

Side Effects

Adverse reactions may occur with any antihypertensive therapy and should be monitored.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Flushing: transient warmth and redness of the skin.
  • Peripheral edema: swelling of ankles or lower limbs.
  • Dizziness or light‑headedness, especially after standing.
  • Tachycardia: increased heart rate.
  • Palpitations: sensation of irregular heartbeat.

Serious or Rare Side Effects

  • Angioedema: swelling of face, lips, tongue, or throat.
  • Severe hypotension: marked drop in blood pressure causing fainting.
  • Myocardial infarction: rare occurrence of heart attack.
  • Hepatic dysfunction: abnormal liver enzyme elevations.
  • Severe allergic reaction: rash, itching, or anaphylaxis.

Precautions & Warnings

Patients and prescribers should consider several safety aspects before initiating therapy.

  • Blood pressure monitoring: regularly assess to avoid excessive hypotension.
  • Hepatic impairment: use with caution and adjust dose if needed.
  • Elderly patients: start at lower dose and monitor for dizziness.
  • Concomitant antihypertensives: watch for additive blood‑pressure lowering effects.
  • Severe aortic stenosis: avoid use due to risk of reflex tachycardia.
  • Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Lercanidipine may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase plasma levels.
  • Grapefruit juice: may elevate drug concentration leading to hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness.

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response.
  • Other antihypertensives (beta‑blockers, diuretics): may cause additive blood‑pressure lowering.
  • Lipid‑lowering agents (statins): monitor for increased statin exposure.

Frequently Asked Questions

Lercanidipin Accord contains lercanidipine, a calcium channel blocker that is prescribed to lower high blood pressure in adults with hypertension. By relaxing arterial smooth muscle, it helps achieve target blood‑pressure levels and reduces the risk of cardiovascular complications.

Lercanidipine selectively blocks L‑type calcium channels in the smooth muscle of blood vessels. This inhibition prevents calcium‑dependent contraction, causing vasodilation, reduced peripheral resistance, and a subsequent fall in systemic blood pressure without significantly affecting heart rate.

The appropriate dose of Lercanidipin Accord is determined by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and any concomitant medications. The prescriber will select the starting dose and any necessary adjustments.

Safety of lercanidipine in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Lercanidipin Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, which primarily induces arterial vasodilation. Compared with ACE inhibitors or beta‑blockers, it has a lower incidence of cough and metabolic effects, but may cause peripheral edema more frequently. Choice of therapy depends on patient‑specific factors and comorbidities.

Lercanidipin Accord should be stored at temperatures below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Lercanidipin Accord is taken orally, usually once daily in the morning, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious adverse events, although rare, can include severe hypotension, angioedema, myocardial infarction, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden chest pain, or unexplained fainting.

Lercanidipin Accord is contraindicated in patients with known hypersensitivity to lercanidipine or any excipients, in those with severe aortic stenosis, and in individuals taking strong CYP3A4 inhibitors such as ketoconazole or clarithromycin. Clinicians should evaluate each patient’s medical history before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lercanidipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT